{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T22:35:25Z","timestamp":1783809325116,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2025M773810"],"award-info":[{"award-number":["2025M773810"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["CCNU25JC030"],"award-info":[{"award-number":["CCNU25JC030"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2022YFD1700200"],"award-info":[{"award-number":["2022YFD1700200"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Hubei Province Natural Science Foundation","doi-asserted-by":"publisher","award":["2023AFB987"],"award-info":[{"award-number":["2023AFB987"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017941","name":"Postdoctoral Science Foundation of Hubei Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017941","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012152","name":"National Postdoctoral Program for Innovative Talents","doi-asserted-by":"publisher","award":["BX20240133"],"award-info":[{"award-number":["BX20240133"]}],"id":[{"id":"10.13039\/501100012152","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.bioorg.2025.108925","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T15:09:59Z","timestamp":1756307399000},"page":"108925","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Design, synthesis, and biological evaluation of 2-substituted-pyridin-4-yl macrocyclic derivatives as new selective HPK1 inhibitors"],"prefix":"10.1016","volume":"165","author":[{"given":"Cheng-Xiang","family":"Duan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Long","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Yu","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong-Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Xing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Shu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang-Fu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.bioorg.2025.108925_bb0005","article-title":"Pharmacological inhibition of hematopoietic progenitor kinase 1 positively regulates T-cell function","volume":"15","author":"Wang","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108925_bb0010","article-title":"Enhanced antitumor immunity by a novel small molecule HPK1 inhibitor","volume":"9","author":"Dan","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108925_bb0015","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.str.2018.10.025","article-title":"Hematopoietic progenitor Kinase-1 structure in a domain-swapped dimer","volume":"27","author":"Wu","year":"2019","journal-title":"Structure"},{"key":"10.1016\/j.bioorg.2025.108925_bb0020","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.55122","article-title":"A perspective on HPK1 as a novel immuno-oncology drug target","volume":"9","author":"Sawasdikosol","year":"2020","journal-title":"eLife"},{"issue":"10","key":"10.1016\/j.bioorg.2025.108925_bb0025","doi-asserted-by":"crossref","first-page":"6187","DOI":"10.4049\/jimmunol.0802631","article-title":"Hematopoietic progenitor kinase 1 is a negative regulator of dendritic cell activation","volume":"182","author":"Alzabin","year":"2009","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108925_bb0030","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/ni1416","article-title":"Hematopoietic progenitor kinase 1 negatively regulates T cell receptor signaling and T cell\u2013mediated immune responses","volume":"8","author":"Shui","year":"2007","journal-title":"Nat. Immunol."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108925_bb0035","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.08.001","article-title":"Hematopoietic progenitor Kinase1 (HPK1) mediates T cell dysfunction and is a Druggable target for T cell-based immunotherapies","volume":"38","author":"Si","year":"2020","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.bioorg.2025.108925_bb0040","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/13543776.2021.1924671","article-title":"Inhibitors of immuno-oncology target HPK1 - a patent review (2016 to 2020)","volume":"31","author":"Linney","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.bioorg.2025.108925_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114819","article-title":"The development of small-molecule inhibitors targeting HPK1","volume":"244","author":"Zhou","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108925_bb0050","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"11","key":"10.1016\/j.bioorg.2025.108925_bb0055","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41573-021-00252-y","article-title":"Trends in kinase drug discovery: targets, indications and inhibitor design","volume":"20","author":"Attwood","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"8","key":"10.1016\/j.bioorg.2025.108925_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2022.102247","article-title":"Structural features of the protein kinase domain and targeted binding by small-molecule inhibitors","volume":"298","author":"Arter","year":"2022","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.108925_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116540","article-title":"Non-kinase off-target inhibitory activities of clinically-relevant kinase inhibitors","volume":"275","author":"Brauer","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108925_bb0070","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s12929-019-0570-5","article-title":"MAP4K3\/GLK in autoimmune disease, cancer and aging","volume":"26","author":"Chuang","year":"2019","journal-title":"J. Biomed. Sci."},{"issue":"12","key":"10.1016\/j.bioorg.2025.108925_bb0075","doi-asserted-by":"crossref","first-page":"8065","DOI":"10.1021\/acs.jmedchem.2c00172","article-title":"Hematopoietic progenitor kinase 1 in tumor immunology: a medicinal chemistry perspective","volume":"65","author":"Zhu","year":"2022","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.bioorg.2025.108925_bb0080","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.tibs.2017.11.008","article-title":"Mechanisms of initiation and propagation","volume":"43","author":"Courtney","year":"2018","journal-title":"Trends Biochem. Sci."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108925_bb0085","first-page":"1163","article-title":"A Story of Kinases and Adaptors: The Role of Lck, ZAP-70 and LAT in Switch Panel Governing T-Cell Development and Activation","volume":"12","author":"Fern\u00e1ndez-Aguilar","year":"2023","journal-title":"Biology (Basel)"},{"issue":"1","key":"10.1016\/j.bioorg.2025.108925_bb0090","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","article-title":"T cell receptor (TCR) signaling in health and disease","volume":"6","author":"Shah","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"11","key":"10.1016\/j.bioorg.2025.108925_bb0095","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/nbt.1990","article-title":"Comprehensive analysis of kinase inhibitor selectivity","volume":"29","author":"Davis","year":"2011","journal-title":"Nat. Biotechnol."},{"issue":"10","key":"10.1016\/j.bioorg.2025.108925_bb0100","doi-asserted-by":"crossref","first-page":"10439","DOI":"10.1021\/acs.jmedchem.5c00762","article-title":"Structure-guided optimization of 2-Aminoquinazoline hematopoietic progenitor kinase 1 inhibitors for improved Oral bioavailability and synergistic antitumor immunity","volume":"68","author":"Wan","year":"2025","journal-title":"J. Med. Chem."},{"issue":"4","key":"10.1016\/j.bioorg.2025.108925_bb0105","doi-asserted-by":"crossref","first-page":"4582","DOI":"10.1021\/acs.jmedchem.4c02631","article-title":"Grimster, discovery and optimization of pyrazine Carboxamide AZ3246, a selective HPK1 inhibitor","volume":"68","author":"Shields","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108925_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108158","article-title":"Discovery of 1,2,4-benzotriazine derivatives as new hematopoietic progenitor kinase 1 (HPK1) inhibitors","volume":"156","author":"Mao","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108925_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117289","article-title":"Research progress in bifunctional small molecules for cancer immunotherapy","volume":"286","author":"Cheng","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"23","key":"10.1016\/j.bioorg.2025.108925_bb0120","doi-asserted-by":"crossref","first-page":"21520","DOI":"10.1021\/acs.jmedchem.4c02421","article-title":"Discovery of Pyridine-2-Carboxamides derivatives as potent and selective HPK1 inhibitors for the treatment of Cancer","volume":"67","author":"Peng","year":"2024","journal-title":"J. Med. Chem."},{"issue":"24","key":"10.1016\/j.bioorg.2025.108925_bb0125","doi-asserted-by":"crossref","first-page":"22002","DOI":"10.1021\/acs.jmedchem.4c01930","article-title":"Discovery of PF-07265028, a selective small molecule inhibitor of hematopoietic progenitor kinase 1 (HPK1) for the treatment of Cancer","volume":"67","author":"Gallego","year":"2024","journal-title":"J. Med. Chem."},{"issue":"19","key":"10.1016\/j.bioorg.2025.108925_bb0130","doi-asserted-by":"crossref","first-page":"17429","DOI":"10.1021\/acs.jmedchem.4c01325","article-title":"Discovery of BAY-405: An Azaindole-based MAP4K1 inhibitor for the enhancement of T-cell immunity against Cancer","volume":"67","author":"Mowat","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108925_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116206","article-title":"Discovery of novel, potent, selective and orally bioavailable HPK1 inhibitor for enhancing the efficacy of anti-PD-L1 antibody","volume":"267","author":"Zeng","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108925_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116877","article-title":"Discovery of 1(2H)-phthalazinone and 1(2H)-isoquinolinone derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors","volume":"279","author":"Peng","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108925_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116310","article-title":"Discovery of 5-aminopyrido[2,3-d]pyrimidin-7(8H)-one derivatives as new hematopoietic progenitor kinase 1 (HPK1) inhibitors","volume":"269","author":"Qiu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"9","key":"10.1016\/j.bioorg.2025.108925_bb0150","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1021\/acsmedchemlett.4c00319","article-title":"Discovery of GNE-6893, a potent, selective, orally bioavailable small molecule inhibitor of HPK1","volume":"15","author":"Tellis","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"issue":"8_Supplement_1","key":"10.1016\/j.bioorg.2025.108925_bb0155","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1158\/1538-7445.AM2025-2239","article-title":"Abstract 2239: FB849, a highly selective HPK1 inhibitor, reshapes the tumor immune microenvironment by modulating various immune cells","volume":"85","author":"Lim","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.108925_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107454","article-title":"Design, synthesis, and biological evaluation of 2,4-diaminopyrimidine derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors","volume":"148","author":"Fu","year":"2024","journal-title":"Bioorg. Chem."},{"issue":"7","key":"10.1016\/j.bioorg.2025.108925_bb0165","doi-asserted-by":"crossref","first-page":"4888","DOI":"10.1021\/acs.jmedchem.2c02038","article-title":"Design and synthesis of functionally active 5-Amino-6-aryl Pyrrolopyrimidine inhibitors of hematopoietic progenitor kinase 1","volume":"66","author":"Gallego","year":"2023","journal-title":"J. Med. Chem."},{"issue":"23","key":"10.1016\/j.bioorg.2025.108925_bb0170","doi-asserted-by":"crossref","first-page":"16201","DOI":"10.1021\/acs.jmedchem.3c01571","article-title":"Design, synthesis, and pharmacological evaluation of Isoindoline analogues as new HPK1 inhibitors","volume":"66","author":"Xie","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108925_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115355","article-title":"Discovery of 7H-Pyrrolo[2,3-d]pyrimidine derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors","volume":"254","author":"Wu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108925_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106728","article-title":"Discovery of potent and selective HPK1 inhibitors based on the 2,4-disubstituted pyrimidine scaffold with immune modulatory properties for ameliorating T cell exhaustion","volume":"139","author":"Zeng","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.108925_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.115064","article-title":"Development of a series of quinazoline-2,5-diamine derivatives as potent hematopoietic progenitor kinase 1 (HPK1) inhibitors","volume":"248","author":"Shi","year":"2023","journal-title":"Eur. J. Med. Chem."},{"issue":"12_Supplement","key":"10.1016\/j.bioorg.2025.108925_bb0190","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1158\/1538-7445.AM2022-5541","article-title":"Abstract 5541: BGB-15025, a potent and selective HPK1 inhibitor, is efficacious as a single agent or in combination with PD-1 antibody in multiple tumor models","volume":"82","author":"Liu","year":"2022","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108925_bb0195","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1021\/acsmedchemlett.2c00238","article-title":"Discovery of Pyrazolopyridine derivatives as HPK1 inhibitors","volume":"14","author":"Ye","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108925_bb0200","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1021\/acsmedchemlett.1c00473","article-title":"Discovery of Spiro-azaindoline inhibitors of hematopoietic progenitor kinase 1 (HPK1)","volume":"13","author":"Chan","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108925_bb0205","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/acsmedchemlett.0c00672","article-title":"Identification of potent reverse Indazole inhibitors for HPK1","volume":"12","author":"Yu","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"issue":"3","key":"10.1016\/j.bioorg.2025.108925_bb0210","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1021\/acsmedchemlett.0c00660","article-title":"Discovery of orally active Isofuranones as potent, selective inhibitors of Hematopoetic progenitor kinase 1","volume":"12","author":"Degnan","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"issue":"1","key":"10.1016\/j.bioorg.2025.108925_bb0215","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1021\/acs.jmedchem.2c01551","article-title":"Discovery of macrocycle-based HPK1 inhibitors for T-cell-based immunotherapy","volume":"66","author":"Wang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.108925_bb0220","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.2147\/DDDT.S329547","article-title":"The expanding role of pyridine and Dihydropyridine scaffolds in drug design","volume":"15","author":"Ling","year":"2021","journal-title":"Drug Des. Devel. Ther."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825008053?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825008053?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T20:10:43Z","timestamp":1772827843000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825008053"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":44,"alternative-id":["S0045206825008053"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108925","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and biological evaluation of 2-substituted-pyridin-4-yl macrocyclic derivatives as new selective HPK1 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.108925","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108925"}}